PMC:7228307 / 44133-44254 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"797","span":{"begin":14,"end":18},"obj":"Gene"},{"id":"798","span":{"begin":81,"end":88},"obj":"Gene"},{"id":"837","span":{"begin":26,"end":31},"obj":"Mutation"},{"id":"838","span":{"begin":33,"end":38},"obj":"Mutation"},{"id":"839","span":{"begin":40,"end":45},"obj":"Mutation"},{"id":"840","span":{"begin":47,"end":52},"obj":"Mutation"},{"id":"841","span":{"begin":54,"end":59},"obj":"Mutation"}],"attributes":[{"id":"A797","pred":"tao:has_database_id","subj":"797","obj":"Gene:2064"},{"id":"A798","pred":"tao:has_database_id","subj":"798","obj":"Gene:2214"},{"id":"A837","pred":"tao:has_standard_notation","subj":"837","obj":"p.F243L"},{"id":"A838","pred":"tao:has_standard_notation","subj":"838","obj":"p.L235V"},{"id":"A839","pred":"tao:has_standard_notation","subj":"839","obj":"p.R292P"},{"id":"A840","pred":"tao:has_standard_notation","subj":"840","obj":"p.Y300L"},{"id":"A841","pred":"tao:has_standard_notation","subj":"841","obj":"p.P396L"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Margetuximab HER2 IgG1 F243L; L235V; R292P; Y300L; P396L Selectively enhance FcγRIII interaction Oncology Phase III"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T782","span":{"begin":81,"end":83},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"}],"text":"Margetuximab HER2 IgG1 F243L; L235V; R292P; Y300L; P396L Selectively enhance FcγRIII interaction Oncology Phase III"}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"798","span":{"begin":81,"end":88},"obj":"Gene"},{"id":"837","span":{"begin":26,"end":31},"obj":"Mutation"},{"id":"838","span":{"begin":33,"end":38},"obj":"Mutation"},{"id":"839","span":{"begin":40,"end":45},"obj":"Mutation"},{"id":"840","span":{"begin":47,"end":52},"obj":"Mutation"},{"id":"841","span":{"begin":54,"end":59},"obj":"Mutation"}],"attributes":[{"id":"A840","pred":"pubann:has_HGVS_notation","subj":"840","obj":"p.Y300L"},{"id":"A838","pred":"pubann:has_HGVS_notation","subj":"838","obj":"p.L235V"},{"id":"A837","pred":"pubann:has_HGVS_notation","subj":"837","obj":"p.F243L"},{"id":"A841","pred":"pubann:has_HGVS_notation","subj":"841","obj":"p.P396L"},{"id":"A798","pred":"pubann:denotes","subj":"798","obj":"Gene:2214"},{"id":"A839","pred":"pubann:has_HGVS_notation","subj":"839","obj":"p.R292P"}],"text":"Margetuximab HER2 IgG1 F243L; L235V; R292P; Y300L; P396L Selectively enhance FcγRIII interaction Oncology Phase III"}

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T252","span":{"begin":0,"end":121},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Margetuximab HER2 IgG1 F243L; L235V; R292P; Y300L; P396L Selectively enhance FcγRIII interaction Oncology Phase III"}

{"project":"LitCovid-sample-PD-HP","denotations":[{"id":"T21","span":{"begin":102,"end":110},"obj":"Phenotype"}],"attributes":[{"id":"A21","pred":"hp_id","subj":"T21","obj":"http://purl.obolibrary.org/obo/HP_0002664"}],"text":"Margetuximab HER2 IgG1 F243L; L235V; R292P; Y300L; P396L Selectively enhance FcγRIII interaction Oncology Phase III"}

{"project":"LitCovid-sentences","denotations":[{"id":"T252","span":{"begin":0,"end":121},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Margetuximab HER2 IgG1 F243L; L235V; R292P; Y300L; P396L Selectively enhance FcγRIII interaction Oncology Phase III"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T21","span":{"begin":102,"end":110},"obj":"Phenotype"}],"attributes":[{"id":"A21","pred":"hp_id","subj":"T21","obj":"http://purl.obolibrary.org/obo/HP_0002664"}],"text":"Margetuximab HER2 IgG1 F243L; L235V; R292P; Y300L; P396L Selectively enhance FcγRIII interaction Oncology Phase III"}